Johnson & Johnson has decided to close its diabetes care unit, Animas Corp, signaling Animas’ exit from the insulin pump business.
After failing to find a buyer, Animas is shutting its business in United States and Canada. The decision will affect around 400 U.S. workers. J&J has been reviewing strategic options, including a potential sale of its diabetes care division, which includes LifeScan Inc, Animas Corp and Calibra Medical Inc.
Animas will be working with rival, Medtronic, to transition the nearly 90,000 patients using Animas pumps to pumps made by Medtronic.
Read the Reuters article